Curasight A/S (CPH:CURAS), a Denmark-based clinical stage radiopharmaceutical company, on Monday reported encouraging preliminary data from the first patient dosed in the ongoing Phase 1 uTREAT clinical trial in patients with high-grade gliomas.

uTREAT targets uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumours.

Position emission tomography (PET)-images from the first treated patient showed clear and sustained uptake of uTREAT in the tumour, confirming that the drug successfully targets cancer tissue. The signal remained visible for at least 24 hours, indicating prolonged tumour binding and supporting the potential for effective radiation delivery to the tumour. The patient's PET signal persisted until the last PET scan (24 hours), demonstrating that uTREAT has protracted binding kinetics, translating to a maximised tumour absorbed dose.

According to Curasight, these early results provide support for its uPAR-targeted approach in radiopharmaceuticals and the potential of uTREAT as a novel therapy for patients with high-grade gliomas and other uPAR expressing aggressive solid tumours (over 85% of solid tumours).

The preliminary dosimetry readout of uTREAT was in line with expectations.

Ulrich Krasilnikoff, Curasight CEO, said: "This first-patient data represents an important early milestone for Curasight and uTREAT. The clear tumour uptake and high retention observed in aggressive glioblastoma provide early clinical validation of our uPAR-targeted radiopharmaceutical approach. The results further support the potential of uTREAT as a next generation radiopharmaceutical targeting uPAR for multiple solid aggressive tumours using one drug and one target. It further supports our theranostic uPAR platform designed to provide highly specific and personalised treatment for certain types of cancer."